Curaleaf Holdings (CURLF) Gross Margin (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Gross Margin of 48.51% for Q1 2026, down 222.0% year-on-year from 39.76% in Q1 2025, and down 4.09% on a QoQ basis from 50.58% in Q4 2025.
Curaleaf Holdings (CURLF) Gross Margin (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Gross Margin for 8 consecutive years, with 48.51% the latest figure, recorded in Q1 2026.
- Quarterly Gross Margin fell 222.0% year-over-year to 48.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.37% (up 57.0% YoY) and the FY2025 annual result came in at 49.76%, up 174.0% from the prior year.
- Gross Margin fell to 48.51% in Q1 2026 per CURLF's latest filing, from 50.58% in the prior quarter.
- Over the last five years, Gross Margin for CURLF reached as high as 57.42% in Q1 2022 and fell as low as 22.23% in Q4 2022.
- A 5-year average of 47.6% and a median of 48.51% in 2026 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin sank 2540 bps — and 2023, when it surged 2301 bps.
- Year by year, Gross Margin stood at 22.23% in 2022, then jumped by 103 bps to 45.24% in 2023, then rose by 9 bps to 49.26% in 2024, then rose by 3 bps to 50.58% in 2025, then retreated by 4 bps to 48.51% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 48.51%, 50.58%, and 49.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 48.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.51% |
| Dec 31, 2025 | 50.58% |
| Sep 30, 2025 | 49.88% |
| Jun 30, 2025 | 48.50% |
| Mar 31, 2025 | 50.74% |
| Dec 31, 2024 | 49.26% |
| Sep 30, 2024 | 48.56% |
| Jun 30, 2024 | 46.88% |
| Mar 31, 2024 | 47.47% |
| Dec 31, 2023 | 45.24% |
| Sep 30, 2023 | 45.04% |
| Jun 30, 2023 | 44.04% |
| Mar 31, 2023 | 48.23% |
| Dec 31, 2022 | 22.23% |
| Sep 30, 2022 | 51.66% |
| Jun 30, 2022 | 54.95% |
| Mar 31, 2022 | 57.42% |
| Dec 31, 2021 | 47.63% |
| Sep 30, 2021 | 57.73% |
| Jun 30, 2021 | 59.11% |